DiaMedica Therapeutics Statistics Share Statistics DiaMedica Therapeutics has 51.69M
shares outstanding. The number of shares has increased by 0.32%
in one year.
Shares Outstanding 51.69M Shares Change (YoY) 0.32% Shares Change (QoQ) 0.06% Owned by Institutions (%) 17.54% Shares Floating 22.77M Failed to Deliver (FTD) Shares 239 FTD / Avg. Volume 0.07%
Short Selling Information The latest short interest is 3.83M, so 7.41% of the outstanding
shares have been sold short.
Short Interest 3.83M Short % of Shares Out 7.41% Short % of Float 10.7% Short Ratio (days to cover) 10.41
Valuation Ratios The PE ratio is -8.98 and the forward
PE ratio is -7.26.
DiaMedica Therapeutics's PEG ratio is
0.
PE Ratio -8.98 Forward PE -7.26 PS Ratio 0 Forward PS 5.9 PB Ratio 5.39 P/FCF Ratio -9.93 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for DiaMedica Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.28,
with a Debt / Equity ratio of 0.01.
Current Ratio 8.28 Quick Ratio 8.28 Debt / Equity 0.01 Debt / EBITDA -0.01 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-905.33K Employee Count 27 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 30K Effective Tax Rate -0.12%
Stock Price Statistics The stock price has increased by 52.36% in the
last 52 weeks. The beta is 1.4, so DiaMedica Therapeutics's
price volatility has been higher than the market average.
Beta 1.4 52-Week Price Change 52.36% 50-Day Moving Average 4.8 200-Day Moving Average 4.86 Relative Strength Index (RSI) 63.35 Average Volume (20 Days) 350,088
Income Statement
Revenue n/a Gross Profit -39K Operating Income -26.68M Net Income -24.44M EBITDA -24.38M EBIT -24.41M Earnings Per Share (EPS) -0.6
Full Income Statement Balance Sheet The company has 3.02M in cash and 340K in
debt, giving a net cash position of 2.69M.
Cash & Cash Equivalents 3.02M Total Debt 340K Net Cash 2.69M Retained Earnings -140M Total Assets 31.47M Working Capital 26.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -22.08M
and capital expenditures -25K, giving a free cash flow of -22.1M.
Operating Cash Flow -22.08M Capital Expenditures -25K Free Cash Flow -22.1M FCF Per Share -0.55
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields DMAC does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for DMAC is $12,
which is 95.4% higher than the current price. The consensus rating is "Strong Buy".
Price Target $12 Price Target Difference 95.4% Analyst Consensus Strong Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 15, 2018. It was a
backward
split with a ratio of 1:20.
Last Split Date Nov 15, 2018 Split Type backward Split Ratio 1:20
Scores Altman Z-Score 29.66 Piotroski F-Score 2
